Skip to main content
Register
Medicine Matters Diabetes
TOOLBAR 1 2 3 4
SEARCH
MENU 1 2 3 4
Close search form
main-content

Medication

Healthcare costs

06-23-2018 | Medication adherence | Article

Cost-related medication non-adherence among US adults with diabetes

Kang H et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.06.016

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

06-06-2018 | Gestational diabetes | Article

Using technology to support care in gestational diabetes mellitus: Quantitative outcomes of an exploratory randomised control trial of adjunct telemedicine for gestational diabetes mellitus (TeleGDM)

Rasekaba TM et al. Diabetes Res Clin Prac 2018; 142: 276–285. doi: 10.1016/j.diabres.2018.05.049

05-09-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

03-16-2018 | Type 2 diabetes | Article

Effect of screening for type 2 diabetes on healthcare costs: A register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009

Sortsø C et al. Diabetologia 2018; 61: 1306–1314. doi: 10.1007/s00125-018-4594-2

04-30-2018 | Insulin degludec | Article

DEVOTE 5: Evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal–bolus regimens for type 2 diabetes in the UK

Pollock RF et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0430-4

04-19-2018 | Type 2 diabetes | Article

Treatment intensification in type 2 diabetes: A real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin

Blonde L et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0429-x

04-11-2018 | Insulin | Article

Adherence to basal insulin therapy among people with type 2 diabetes: A retrospective cohort study of costs and patient outcomes

Perez-Nieves M et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0421-5

02-21-2018 | Insulin aspart | Review | Article

15 years of experience with biphasic insulin aspart 30 in type 2 diabetes

Liebl A et al. Drugs R D 2018; 18: 27–39. doi: 10.1007/s40268-018-0228-x

02-06-2018 | Healthcare costs | Article

Cost-effectiveness analysis of canagliflozin 300 mg versus dapagliflozin 10 mg added to metformin in patients with type 2 diabetes in the United States

Neslusan C et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0371-y

09-06-2017 | Healthcare costs | View from the clinic | Article

The rising cost of medication: Groceries or insulin?

Advisory Board member and Family Physician, Allison Petznick, highlights the impact of rising medication costs on one of her patients, and provides practical suggestions for US physicians to help those struggling to manage the everyday costs of type 2 diabetes.

04-15-2005 | Hypertension | Article

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes

Clarke PM et al. Diabetologia 2005; 48: 868–877. doi: 10.1007/s00125-005-1717-3

03-01-2001 | Metformin | Article

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes

Clarke P et al. Diabetologia 2001; 44: 298–304. doi: 10.1007/s001250051617


More on diabetes medications


« Back to main page | Adherence | Adverse effects | Alpha-glucosidase inhibitors | Amylin analogs | Anti-hypertensive medications | Anti-obesity medications | Cardiovascular disease | Clinical trials | Diabetic complications | DPP-4 inhibitors | Gestational diabetes and pregnancy | Glinides | GLP-1 receptor agonists | Glycemic control | Guidelines | Healthcare costs | Insulins | Lipid-lowering medications | Metformin | Oral combination medications | Other medication classes | Pediatrics | SGLT2 inhibitors | Specific populations | Sulfonylureas | Thiazolidinediones | Type 1 diabetes | Type 2 diabetes


Image Credits

Version: 0.1-SNAPSHOT